会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 8. 发明公开
    • 인간 배아줄기세포 유래 혈관주위 전구세포의 제조방법 및 이를 포함하는 세포치료 조성물
    • 用于生产人胚胎干细胞衍生的外源性原核细胞的方法和包含其的细胞疗法的组合物
    • KR1020130085308A
    • 2013-07-29
    • KR1020120006371
    • 2012-01-19
    • (주)차바이오텍차의과학대학교 산학협력단
    • 김정모송원경정형민
    • C12N5/071C12N5/00C12N9/76
    • C12N5/0692A61K35/00C12N5/0662C12N2501/155C12N2506/02C12N5/0068C12N9/6427C12N2501/105C12N2501/165C12N2533/52C12N2533/54
    • PURPOSE: A manufacturing method of a human embryonic stem cell originated pericyte progenitor cell is provided to manufacture a human embryonic stem cell originated pericyte progenitor cell which is able to be useful as a cytotherapy composition for treatment or prevention of cardiovascular diseases or retinal disorders. CONSTITUTION: A manufacturing method of a pericyte progenitor cell from a stem cell comprises 1) a step of treating a stem cell originated embryoid body with a bone morphogenetic protein 4 (BMP4) growth factor to differentiate to a mesodermal cell; 2) a step of isolating the embryoid body including the differentiated mesodermal cell to a single cell; and 3) a step of cultivating the isolated single cell in a petri dish coated with a substrate, and proliferating the attached cells only by natural selection; The stem cell in step 1) is selected from the group consisting of human embryonic stem cell, induced pluripotent stem cell (iPSC) and somatic cell nuclear transfer cell (SCNT). A pharmaceutical composition for prevention and treatment of cardiovascular diseases includes the pericyte progenitor cell as an active ingredient.
    • 目的:提供一种人胚胎干细胞产生的周细胞祖细胞的制造方法,用于制造能够用作治疗或预防心血管疾病或视网膜疾病的细胞疗法组合物的源于人胚胎干细胞的周细胞祖细胞。 构成:来自干细胞的周细胞祖细胞的制造方法包括1)用骨形态发生蛋白4(BMP4)生长因子处理源自干细胞的胚状体的步骤,以分化成中胚层细胞; 2)将包括分化的中胚层细胞的胚状体分离成单个细胞的步骤; 和3)在涂覆有底物的陪替氏培养皿中培养分离的单细胞的步骤,并且仅通过自然选择增殖附着的细胞; 步骤1)中的干细胞选自人胚胎干细胞,诱导多能干细胞(iPSC)和体细胞核转移细胞(SCNT)。 用于预防和治疗心血管疾病的药物组合物包括周细胞祖细胞作为活性成分。